Literature DB >> 9387858

Murine vesicular monoamine transporter 2: molecular cloning and genomic structure.

N Takahashi1, G Uhl.   

Abstract

The principal brain vesicular monoamine transporter (VMAT2) pumps monoamines including dopamine, norepinephrine, serotonin and histamine from neuronal cytoplasm into synaptic vesicles and is implicated in actions of certain psychostimulants and selective neurotoxins. To improve understanding of this gene and its regulation, and to facilitate study of the roles played by this important molecule in mouse genetic models, we have cloned murine VMAT2 cDNA and genomic sequences. A 4.2-kb mouse VMAT2 cDNA hybridized to a 4.3-kb mRNA expressed chiefly in brainstem. Murine cDNA and genomic DNA analyses reveal an open reading frame of 1551 bp encoding 517 amino acids that display 92, 96 and 60% amino-acid identity with human and rat VMAT2, and rat vesicular acetylcholine transporter sequences, respectively. This open reading frame is distributed over 15 of 16 identified exons, and spans > 35 kb of genomic DNA. A major transcriptional initiation site is identified 107 bp 5' to the translational initiation ATG codon using primer extension/5' rapid amplification of cDNA ends. Sequences immediately 5' of this putative transcription start site lack 'TATA' or 'CATT' boxes, but contain consensus sequences that may bind cAMP response element, Sp1, AP2 and other transcription factors. Identification of these genomic sequences facilitates construction of homologous recombinant mice, provides a template for gene structures in the vesicular transporter family, and identifies sequences elements that could contribute to the specific patterns of regulated VMAT2 expression in monoaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9387858     DOI: 10.1016/s0169-328x(97)00116-2

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

1.  Tuning pacemaker frequency of individual dopaminergic neurons by Kv4.3L and KChip3.1 transcription.

Authors:  B Liss; O Franz; S Sewing; R Bruns; H Neuhoff; J Roeper
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

2.  Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism.

Authors:  K A Mooslehner; P M Chan; W Xu; L Liu; C Smadja; T Humby; N D Allen; L S Wilkinson; P C Emson
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.

Authors:  N Drandarevski; A Marburger; D Walther; T Reum; G Uh; R Morgenstern
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 4.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

5.  N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

Authors:  B Torres; A E Ruoho
Journal:  Neuroscience       Date:  2013-12-07       Impact factor: 3.590

6.  Transcriptional activation of vesicular monoamine transporter 2 in the pre-B cell line Ea3.123.

Authors:  F Watson; D G Deavall; J A Macro; R Kiernan; R Dimaline
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

7.  Resting-state functional connectivity and presynaptic monoamine signaling in Alcohol Dependence.

Authors:  Xi Zhu; Nisha Dutta; Sarah G Helton; Melanie Schwandt; Jia Yan; Colin A Hodgkinson; Carlos R Cortes; Mike Kerich; Samuel Hall; Hui Sun; Monte Phillips; Reza Momenan; Falk W Lohoff
Journal:  Hum Brain Mapp       Date:  2015-09-14       Impact factor: 5.038

8.  Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Authors:  F S Hall; K Itokawa; A Schmitt; R Moessner; I Sora; K P Lesch; G R Uhl
Journal:  Neuropharmacology       Date:  2013-08-24       Impact factor: 5.250

9.  Targeting barrel field spiny stellate cells using a vesicular monoaminergic transporter 2-Cre mouse line.

Authors:  Aikeremu Ahemaiti; Hannah M Weman; Fabio B Freitag; Katharina Ambroz; Malin C Lagerström
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.